Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–92 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atherosclerotic Coronary Vascular Disease Clear all
Active, not recruiting Phase 4 Interventional

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

NCT06249165
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Recruiting Phase 3 Interventional

The Prevent Coronary Artery Disease Trial

NCT06494501
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
30 Years to 50 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 22, 2026, 10:50 AM EDT
Completed No phase listed Observational

Incident COronary EveNts Identified by Computed Tomography

NCT02959099
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Miami, Florida • Bethesda, Maryland • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 22, 2026, 10:50 AM EDT
Recruiting Phase 2 Interventional

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

NCT06927739
View directory record Official record
Conditions
Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease, Myocardial Infarct, Atherosclerotic Coronary Vascular Disease
Interventions
Orticumab, Placebo
Drug
Lead sponsor
Abcentra
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Torrance, California • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

NCT01500434
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
21
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 22, 2026, 10:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT07083557
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions
Endothelial cell collection
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

NCT04992065
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 22, 2026, 10:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation Between Coronary and Carotid Atherosclerotic Disease and Links With Clinical Outcomes

NCT02114541
View directory record Official record
Conditions
Vascular Disease
Interventions
Not listed
Lead sponsor
Montreal Heart Institute
Other
Eligibility
18 Years and older
Enrollment
1,339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Torrance, California • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 22, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lipoic Acid and Prevention of Heart Disease

NCT00765310
View directory record Official record
Conditions
Atherosclerosis
Interventions
R-alpha lipoic acid, Placebo
Dietary Supplement
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 22, 2026, 10:50 AM EDT
Terminated No phase listed Observational

The CardiOvascular Remodeling Following Endovascular Aortic Repair (CORE) Study

NCT02735720
View directory record Official record
Conditions
Thoracic Aortic Aneurysm
Interventions
TEVAR, Non-TEVAR medical treatment
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 22, 2026, 10:50 AM EDT
Not listed Not applicable Interventional

Evaluation of Asymptomatic Coronary Atherosclerotic Disease Among People of Kalamazoo, MI

NCT02942342
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis
Interventions
Computed Tomography (CT) Scan
Procedure
Lead sponsor
Borgess Research Institute
Other
Eligibility
35 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 22, 2026, 10:50 AM EDT
Terminated No phase listed Observational

Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study

NCT01341483
View directory record Official record
Conditions
Erectile Dysfunction Due to Arterial Insufficiency
Interventions
Not listed
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
35 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Phase 3 Interventional

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Completed No phase listed Observational

Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)

NCT01178320
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Simvastatin, simvastatin plus extended-release niacin
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
15
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
242
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Active, not recruiting Phase 3 Interventional

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

NCT06305559
View directory record Official record
Conditions
Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 22, 2026, 10:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort

NCT00344903
View directory record Official record
Conditions
Atherosclerosis, Congestive Heart Failure, Left Ventricular Hypertrophy, Diabetes Mellitus, Hypertension, Obesity, Metabolic Syndrome X, Myocardial Infarction
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years to 70 Years
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2010 · Synced Oct 22, 2026, 10:50 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

NCT07839936
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions
VERVE-102, Placebo
Drug
Lead sponsor
Verve Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
DeSoto, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 10:50 AM EDT
Completed Not applicable Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels

NCT01498692
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • Ocala, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 22, 2026, 10:50 AM EDT